Category 3 abuse-deterrent study of the abuse-deterrent, extended-release oxycocone product Egalet 002.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 16 Dec 2016
At a glance
- Drugs Oxycodone (Primary)
- Indications Pain
- Focus Adverse reactions
- 16 Dec 2016 According to an Egalet media release, full data from this trial will be presented at a medical meeting in 2017.
- 16 Dec 2016 Results published in an Egalet Media Release
- 25 Aug 2016 According to an Egalet media release, the data of this trial would be presented PAINWeek 2016.